Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1616 1636
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18553774 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | Non-Final OA | Genentech, Inc. |
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | Final Rejection | BASECURE THERAPEUTICS LLC |
| 18335990 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | Non-Final OA | The Board of Regents of The University of Texas System |
| 17626674 | MULTILAMELLAR RNA NANOPARTICLES | Final Rejection | University of Florida Research Foundation, Inc. |
| 17950573 | PRUSSIAN BLUE NANOPARTICLES FUNCTIONALIZATION WITH LATENCY REVERSING AGENTS AND BROADLY NEUTRALIZING ANTIBODIES, AND APPLICATIONS THEREOF | Final Rejection | THE GEORGE WASHINGTON UNIVERSITY |
| 17710783 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | Final Rejection | University of Washington |
| 18015800 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18248988 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Non-Final OA | SANOFI |
| 18427072 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17925225 | CUG REPEAT SEQUENCE BINDING AGENT | Non-Final OA | OSAKA UNIVERSITY |
| 17787089 | SYNTHETIC PROCESSES AND INTERMEDIATES | Non-Final OA | ARBUTUS BIOPHARMA CORPORATION |
| 17501635 | UNIVERSAL MULTI-FUNCTIONAL GSH-RESPONSIVE SILICA NANOPARTICLES FOR DELIVERY OF BIOMOLECULES INTO CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17906134 | COMPOSITIONS AND METHODS COMPRISING IMPROVED GUIDE RNAs | Non-Final OA | Cornell University |
| 18130761 | CONTACT LENS PRODUCT WITH CORNEA REPAIR FUNCTION | Non-Final OA | PEGAVISION CORPORATION |
| 17432237 | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | Non-Final OA | Salk Institute for Biological Studies |
| 17754196 | OLIGONUCLEOTIDE, AND TARGET RNA SITE-SPECIFIC EDITING METHOD | Non-Final OA | Fukuoka University |
| 18032663 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | Non-Final OA | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED |
| 17570498 | BIO-DEGRADABLE MICROCAPSULES | Final Rejection | INTERNATIONAL FLAVORS & FRAGRANCES INC. |
| 18461368 | ENGINEERED IMMUNE CELL THERAPIES | Non-Final OA | Factor Bioscience Inc. |
| 18274496 | SYNERGISTIC EFFECT OF SMN1 AND MIR-23A IN TREATING SPINAL MUSCULAR ATROPHY | Non-Final OA | JOINT STOCK COMPANY «BIOCAD» |
| 17787780 | HISTIDINE-LYSINE POLYMERS AND METHODS FOR DELIVERING MRNA USING THE SAME | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18037234 | UMLILO ANTISENSE TRANSCRIPTION INHIBITORS | Non-Final OA | LEMBA BV |
| 18032329 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Non-Final OA | FELDAN BIO INC. |
| 17633300 | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS | Non-Final OA | Merck Sharp & Dohme Corp. |
| 16608474 | OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF | Non-Final OA | KYOWA KIRIN CO., LTD. |
| 18048577 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | Final Rejection | Arrowhead Pharmaceuticals, Inc. |
| 18002553 | CROSS-LINKING METHODS | Non-Final OA | The University of Bath |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy